Effects of Enalapril Versus

Methds and Results
In the present study, we evaluated the effects of blockade of the RAS by the angiotensin-converting enzyme inhibitor enalapril and the angiotensin II receptor blocker losartan on left ventricular (LV) and right ventricular mass and LV dilation in relation to changes in central hemodynamics during the maintenance of minoxidil and aortocaval shunt-induced cardiac hypertrophy. Both blockers similarly decreased LV end-diastolic pressure (LVEDP) and LV peak systolic pressure, whereas cardiac output remained unchanged in both models of volume overload. This suggests a major contribution of improved LV performance and decreased afterload to the decrease in cardiac preload by the two blockers rather than decreased venous return. Both blockers reversed LV hypertrophy in parallel to their effects on LVEDP in both models of volume overload. In minoxidil-treated rats, the extent of reversal in LV mass and dilation by the two blockers was similar to "spontaneous regression" after discontinuation of minoxidil treatment.
Conclusions These results indicate that in contrast to the development phase of cardiac hypertrophy, the RAS does not contribute to the maintenance of volume overload-induced cardiac hypertrophy in these two models via direct cardiac trophic effects. The RAS, however, maintains cardiac 
Central Hemodynamics
On the day of the study, rats were anesthetized with halothane/nitrous oxide/oxygen, and a PE-50 catheter (Clay Adams) filled with heparinized saline (100 IU/mL) was inserted into the LV via the right common carotid artery and into the right atrium via the right external jugular vein. Catheters were exteriorized on the necks of the animals. After a 4-hour recovery period, LV end-diastolic pressure (LVEDP), LV peak systolic pressure (LVPSP), and right atrial pressure (RAP) were assessed as described by Fields et al. 15 The heart rate was calculated from the curve of LVPSP and LVEDP recorded at a paper speed of 10 mm/s. Resting hemodynamics were assessed in conscious, unrestrained rats after a 30-minute acclimatization period.
Cardiac Morphology
After the assessment of central hemodynamics, under pentobarbital anesthesia the chest cavity was opened, and the heart was arrested in diastole by intravenous injection of 1 mol/L KCl, rapidly excised, and placed into ice-cold saline to remain in diastole and for removal of the blood. After removal of the atria and large vessels, the ventricles were blotted dry, and the RV was dissected along its septal insertion from the rest of the ventricular mass. LV long axis (apex-base distance) and LV and RV wet weights were assessed. Then the mass of the LV was divided by two transverse cuts at one third and two thirds of the length. The middle slice of the LV was used for the assessment of the LV wall thickness and internal diameters as previously described.7 LV and RV dry weights were determined after the tissue was dried in an oven at 37°C for 72 hours. Table 3 ). Enalapril and losartan decreased LVPSP of minoxidil-treated rats and shunt rats to levels similar to those observed in control rats (Table 2 ). In contrast, both drugs decreased MAP of minoxidil-treated rats and shunt rats to values below those of control rats (Table 3 ). There were no differences in heart rate between the different groups at 10 weeks (data not shown). Cardiac index and stroke volume were increased by 20% after 10 weeks of aortocaval shunt or minoxidil treatment (Table 3) . Neither enalapril nor losartan significantly changed cardiac index in control, shunt, or minoxidil-treated animals. Total peripheral resistance index (inclusive shunt) was significantly decreased in shunt rats (Table  3) . Enalapril and losartan did not further decrease total peripheral resistance index in animals with an aortocaval shunt. In minoxidil-treated rats, total peripheral resistance index was significantly decreased and dropped further when either enalapril or losartan was added (Table 3) . LV and RV Weights Aortocaval shunt and minoxidil increased LV weight by 50% and 22%, respectively, at 10 weeks (Fig 1; Table  4 ). Discontinuation of minoxidil after 5 weeks of treatment resulted in a substantial decrease in LV weight at 7 weeks, and LV weight had returned to normal at 10 weeks (Fig 1) . In control rats, both enalapril and losartan decreased LV weight by about 10% (Table 4) . Enalapril decreased LV weight of shunt rats somewhat less (P<.05) than losartan compared with untreated shunt animals, and the remaining hypertrophy in enalapril-and losartan-treated shunt rats was +41% and +32% compared with their respective treated control rats (Table 4 ). In minoxidil-treated rats, enalapril and losartan decreased LV weight similarly back to the level of untreated control rats. However, neither blocker reversed the LV weight to the extent of their respective treated controls, ie, LV weight of rats on minoxidil treated with enalapril or losartan remained to a small but significant extent increased compared with the respective treated control group (Table 4) . Aortocaval shunt and minoxidil treatment increased RV weight by 68% and 24%, respectively (Fig 1; Table   4 ). After discontinuation of minoxidil at 5 weeks, RV weight had substantially decreased at 7 weeks, and at 10 weeks it remained increased by only 6% (P<.05) compared with control rats (Fig 1) . Neither enalapril nor losartan changed RV weight in control rats. However, both drugs significantly reduced RV hypertrophy induced by aortocaval shunt compared with untreated shunt rats (Table 4) . However, in both enalapril-and losartan-treated shunt rats, RV weight remained significantly increased compared with their respective treated control rats. Neither enalapril nor losartan affected RV hypertrophy induced by minoxidil (Table 4) .
Statistical Analysis
There were no differences in percent dry weight of LV and RV between the groups at 10 weeks (data not shown). Relations Between Cardiac Hemodynamic Load and LV Weight Linear regression analysis showed a positive correlation between LV weight and LVEDP in rats with aortocaval shunt and in minoxidil-treated rats (Fig 2) . The regression line for changes in LV weight in relation to changes in LVEDP for aortocaval shunt was steeper than for minoxidil (P<.01), ie, a more pronounced hypertrophic response of the LV for a given increase in LVEDP in volume overload induced by aortocaval shunt than by chronic minoxidil treatment. In rats with volume overload by an aortocaval shunt, enalapril and losartan decreased LV weight in parallel to their effects on LVEDP as assessed from the regression lines (Fig 2) . In rats on minoxidil, losartan decreased LV weight in parallel with its effect on LVEDP, whereas enalapril had a somewhat more (P<.10) pronounced effect on LV weight relative to the decrease in LVEDP (Fig 2) . LV Long Axis, Internal Diameter, Wall Thickness, and Wall Thickness/Radius Ratio Aortocaval shunt and minoxidil increased the LV long axis by 18% and 11%, respectively ( Table 5 ). The LV long axis normalized within 5 weeks after discontinuation of minoxidil (data not shown). In rats on minoxidil, enalapril and losartan decreased the LV long axis to the level of treated and untreated control rats (Table  5 ). In shunt rats, both blockers decreased the LV long axis compared with untreated shunt rats but not to the level of treated and untreated control rats (Table 5) .
Aortocaval shunt increased the LV (major) internal diameter by 19% at 10 weeks. Minoxidil resulted in an increase in LV internal diameter by 17% (Tables 1 and  5 ). The increase in LV internal diameter reversed by 50% within 2 weeks after discontinuation of minoxidil and had nearly normalized at 5 weeks. Both enalapril and losartan decreased the LV internal diameter in control rats, in shunt rats, and in minoxidil-treated rats. However, in both shunt and minoxidil groups, LV internal diameter remained significantly elevated compared with untreated and treated control rats (Table 5) .
Aortocaval shunt and minoxidil caused small (P<.05) increases in LV wall thickness at 10 weeks (Table 5 ). When minoxidil was discontinued at 5 weeks, LV wall thickness returned toward normal within the following 2 to 5 weeks (Table 1) . Enalapril and losartan decreased LV wall thickness in control rats, in shunt rats, and in minoxidil-treated rats (Table 5 ). However, in both shunt and minoxidil-treated rats, LV wall thickness still remained increased compared with their treated controls ( Table 5) . As a result of the above-mentioned remodeling of the LV in response to aortocaval shunt or minoxidil, the ratio of LV wall thickness to radius significantly decreased in minoxidil-treated and shunt rats. This ratio returned to normal after discontinuation of minoxidil ( Table 1 ). Enalapril and losartan somewhat increased (P<.05) this ratio when given to control rats (as a result of a larger decrease in LV internal diameter than in LV wall thickness). Enalapril or losartan added to minoxidil-treated or shunt rats partially reversed this ratio toward normal. However, in both enalapril-and losartan-treated shunt or minoxidil groups, the ratio of LV wall thickness to radius remained significantly lower than in untreated or treated controls (Table 5) . Hematocrit Minoxidil significantly decreased hematocrit at 5 weeks. Hematocrit remained at this level at 7 and 10 weeks of treatment. Discontinuation of minoxidil at 5 weeks resulted in a gradual increase in hematocrit to normal (Table 1) .
Body Weight
Minoxidil significantly increased body weight after 10 weeks of treatment. When minoxidil was discontinued at 5 weeks, body weight returned to normal (compared with control rats) within 2 weeks (data not shown). In minoxidil-treated rats, both enalapril and losartan treatment normalized body weight compared with the control group, but in both groups body weights remained significantly higher than in the respective treated control rats (Table 4) . Aortocaval shunt did not affect body weight at 10 weeks. In shunt rats, enalapril and losartan caused only minor decreases in body weight similar to those observed in control rats (Table 4) . Discussion The present study has two major findings: (1) In both models of volume overload-induced cardiac hypertrophy, losartan and enalapril reduced LV weight similarly and in parallel to their effects on LVEDP. ( 2) The effects of the two blockers on LV mass and LV dilation in minoxidil-treated rats are similar in magnitude to spontaneous regression of minoxidil-induced cardiac changes.
Cardiac Morphology and Hemodynamics During Chronic Aortocaval Shunt or Minoxidil Treatment
Cardiac remodeling in response to cardiac volume overload by aortocaval shunt or chronic minoxidil treatment occurs mostly within the first 3 to 5 weeks with no or minimal changes during subsequent weeks (see References 5 through 8, 17 through 19 , and the present study). In both models, once the new balance between cardiac load and cardiac mass has been established, the LVEDP appears to remain relatively stable,51820 presumably until heart failure develops, resulting in a further rise in LVEDP. 21 The extent of cardiac hypertrophy is correlated with the degree of cardiac volume overload in both models (Fig 2) . However, significantly more LV hypertrophy for a given increase in LVEDP was found in rats with aortocaval shunt than in rats on minoxidil (Fig 2) . These data are consistent with a modulation of the hypertrophic response of the LV to volume overload by nonhemodynamic trophic stimuli such as the RAS or the sympathetic nervous system. Possible changes in cardiac sympathetic activity after aortocaval shunt have not yet been assessed. Both plasma and cardiac renin activity increase shortly after an aortocaval shunt is opened, and we recently showed that the remodeling of the heart by volume overload appears to be potentiated by the RAS.4 Less pronounced and delayed increases in plasma and cardiac renin activity6 during the development of minoxidil-induced cardiac hypertrophy6 may explain a less pronounced hypertrophic response to similar volume overload in this model. Thus, the extent of modulation of the hypertrophic response to volume In rats with an aortocaval shunt, both blockers reversed LV hypertrophy in parallel to their effects on LVEDP (Fig 2) . A nearly normalized LV wall thickness by the two blockers probably reflects the decrease both in LV filling pressures and in cardiac afterload. The two blockers also similarly decreased LV dilation, as reflected in decreases in LV long axis and in LV internal diameter. The extent of regression of RV hypertrophy by either blocker was similar to their effects on LV mass. The partial regression of LV and RV hypertrophy probably reflects that cardiac load remained somewhat increased. However, we cannot exclude that longer treatment would result in further regression.
In minoxidil-treated rats, both blockers normalized LVEDP. Venodilation13 and normalization of the intravascular volume expansion induced by minoxidil (as suggested from body weight) as well as a decrease in blood pressure may contribute to the decrease in LVEDP. Cardiac output, however, remained at the same level as in rats on minoxidil alone. Thus, the decrease in cardiac afterload, and therefore improved emptying of the LV, and possible effects on LV diastolic function by the two blockers (see above), rather than decrease in venous return, appear to cause the decrease in LVEDP.
In minoxidil-treated rats, both blockers returned both LV mass and dimensions (LV long axis and internal diameter) to close to normal. The somewhat larger decrease in blood pressure by enalapril versus losartan (Table 3 ) may explain the slightly more pronounced decrease in LV weight by enalapril than anticipated from its effect on LVEDP. Five weeks of treatment by either blocker reversed LV hypertrophy and dilation to a similar extent, as observed in rats 5 weeks after discontinuation of minoxidil (Fig 1) . There is therefore no evidence for other trophic mechanisms playing a major role in the maintenance of minoxidil-induced LV hypertrophy. Nei-ther blocker, however, significantly reduced RV hypertrophy. This may be related to a persisting increase in load of the RV in terms of minoxidil-induced increase in pulmonary artery pressure. 25 In prevention experiments, enalapril decreased cardiac preload but did not prevent the cardiac remodeling of the LV in response to cardiac volume overload by aortocaval shunt or minoxidil treatment.5,6 Losartan had similar or less pronounced effects on LVEDP but, in contrast to enalapril, prevented/attenuated volume overload-induced changes in cardiac morphology in both models.5S6 We postulated-56 that despite ACE inhibition by enalapril, angiotensin II continued to be generated in the heart, acting as a cardiac trophic stimulus mediating or involved in the cardiac remodeling. These differences between the two blockers, however, do not persist in the maintenance phase in these two models of cardiac volume overload. Both blockers decreased LV mass in parallel with their effect on cardiac preload. Thus, the RAS appears to act as a mediator of the hypertrophic response to the acute increase in hemodynamic load (and thus stretch of cardiomyocytes) in vitro4 and probably in vivo56 but no longer in the chronic phase of volume overload-induced hypertrophy. On the other hand, in both models of cardiac volume overload, hemodynamic effects of the RAS appear to continue to play a major role in determining ifiling pressures of the heart and thereby the maintenance of cardiac hypertrophy.
In conclusion, in both models of volume overloadinduced cardiac hypertrophy, enalapril and losartan reversed LV hypertrophy in parallel to their effects on LVEDP. Thus, in contrast to the development phase, it appears that the RAS does not continue as a cardiac trophic stimulus for the maintenance of cardiac hypertrophy induced by aortocaval shunt and minoxidil treatment but indirectly maintains cardiac hypertrophy by contributing to the persistence of high filling pressures.
